This is an ideal setting for a controlled trial in order to reduce the chances of confounders. NHL patients are especially vulnerable to anthracycline-induced cardiotoxicity. Mean age of NHL diagnosis is in the eight decade of life, a time where cardiovascular comorbidities are frequent, increasing the likelihood of post-therapy heart failure. Another important rationale for choosing this cancer type as a target of this project is that there is a balance in the incidence of NHL diagnoses across genders (60% male/40%female). There is no conclusive information about gender differences in cancer therapy-induced cardiotoxicity. One main reason for this lack of information is that most of the studies evaluating the incidence of cardiotoxicity have been done in breast cancer patients, a malignancy with a very low representation of male patients. Our aim is to extend the results of the project beyond NHL to all cancer patients treated with anthracyclines